A 33-year-old musician walked into his doctor's office to prove he was healthy, and walked out with a prostate cancer diagnosis that doctors at one of the nation's top cancer centers had rarely seen in someone so young.
Joseph Wayne Singleton, frontman of The Urban Kreyol Band and a resident of Opelousas, Louisiana, only scheduled the appointment because his wife pushed him to get a real physical. Singleton held a commercial driver's license, and the annual CDL exams he'd been passing gave him all the reassurance he thought he needed. His wife disagreed. She felt those exams weren't thorough enough.
So Singleton booked a full checkup, not because anything felt wrong, but to settle the argument. As he told Fox News Digital, his thinking was simple.
"My mentality was, 'OK, to make my wife happy, I'm going to do this and prove to her that I'm in perfect shape.'"
He had no symptoms. No warning signs. No family history that raised red flags in his own mind. He was 33 years old and touring the country with his band. Prostate cancer was not on anyone's radar.
During that routine physical, Singleton's doctor made an unusual call. He ordered a PSA blood test, a screening for prostate-specific antigen, a marker that can signal prostate trouble. Most guidelines don't recommend PSA screening until men reach 45 at the earliest, and many push the starting age to 50 or even 55 for men at average risk. Singleton was well below every threshold.
The doctor himself couldn't account for the decision.
"He couldn't explain what made him do that, but he did."
The results came back alarming. Singleton described his PSA levels as "through the roof." A biopsy followed. Then came the diagnosis: prostate cancer, in a man more than a decade younger than the earliest recommended screening age.
Singleton was sent to UT MD Anderson Cancer Center in Houston, one of the country's premier cancer treatment facilities. Doctors there told him they had rarely, if ever, encountered prostate cancer in a patient as young as he was. The cancer is uncommon in men under 40, according to the American Cancer Society.
Singleton underwent a prostatectomy, full removal of the prostate. The recovery, by his own account, went far better than he had braced for.
"A couple of weeks after having the prostatectomy, I was back on airplanes flying across the country doing shows with my band. It wasn't as bad as it possibly could have been."
That timeline is striking. Two weeks from major cancer surgery to boarding a flight and performing. Singleton credits a higher power for the outcome.
"By the grace of God, I'm here now. It was quite an eye-opener. It made me question myself... a lot of 'why me?'"
Now 45, Singleton has had more than a decade to sit with that question. His answer has become a mission. Celebrity cancer disclosures have a track record of prompting others to seek care, as seen when reality star Snooki's cervical cancer disclosure prompted fans to get screened. Singleton sees his own platform the same way.
"I came to the conclusion that because of the platform that I have, being a musician, that maybe it was meant for me to be an advocate. I'm having people reach out to me from all across the country [who are] finding out about my story... and I think it's very important."
His message is blunt: don't wait for symptoms, and don't assume youth makes you bulletproof.
"This could have turned out so much worse had I not gotten tested early. I hate to think what could have happened."
Singleton's case lands in the middle of a broader debate over when prostate cancer screening should begin, and whether current guidelines leave younger men exposed. Robert Smith, Ph.D., senior vice president of cancer screening at the American Cancer Society in Atlanta, told Fox News Digital that the medical community hasn't settled the question.
"The one thing most organizations agree on is that clinicians should discuss prostate cancer screening with men, emphasizing benefits, limitations and harms associated with screening, diagnosis and treatment, rather than issue a direct recommendation to undergo screening."
In plain English: most guidelines tell doctors to have a conversation rather than order the test outright. The recommended starting age varies, 45, 50, or 55, depending on the organization and the patient's risk factors. Black men and men with a family history of cancer face higher risk and are generally advised to start screening between 40 and 45. Recommendations for stopping screening range from 69 to 75, or when life expectancy drops below ten years.
Smith acknowledged that the evidence has shifted. Prostate cancer screening appears more effective at preventing deaths than researchers once believed.
"Over this period, it has become clear that prostate cancer screening is more effective at reducing prostate cancer deaths than was previously believed, and there are new strategies... to mitigate the harms associated with diagnosing and treating prostate cancer."
He also noted that lifestyle factors play a role in reducing cancer risk, the same habits that lower the chances of heart disease and diabetes. Smith added that some studies suggest staying sexually active may lower prostate cancer risk, though he called the results "mixed."
One point Smith made without qualification: regular PSA testing reduces the risk of being diagnosed with advanced prostate cancer. For a man like Singleton, who had no symptoms and no reason to suspect trouble, that single blood draw was the difference between catching the disease early and discovering it after it had spread. The broader question of when and how aggressively men should be screened has taken on new urgency as more public figures share their own diagnoses, including the recent disclosure that Joe Biden's prostate cancer has spread.
Singleton's story is not a policy argument. It's a lived example of what happens when a doctor trusts his instincts over a guideline, and when a wife refuses to accept a checkbox exam as proof of health. Had either one deferred, had the doctor skipped the PSA test because the patient was "too young," or had Singleton brushed off his wife's concern, the cancer would have grown undetected.
The fact that MD Anderson doctors had rarely seen the disease in someone Singleton's age underscores how easily his case could have been missed. Rare doesn't mean impossible, and guidelines built around averages leave outliers unprotected. Biden's own cancer journey, and the conflicting accounts of how his treatment has gone, illustrates how even the most closely monitored patients can face uncertainty once cancer advances.
Several questions remain unanswered. Singleton has not publicly disclosed his specific cancer stage, his exact PSA levels at diagnosis, or whether he has experienced long-term side effects from the surgery. His current cancer status, whether he is in formal remission or under ongoing surveillance, is also unclear. What is clear is that he is alive, performing, and using his platform to push other men toward early screening.
Singleton's advocacy is personal, not institutional. He doesn't appear to be affiliated with a formal cancer organization. He's a working musician from a small Louisiana city who got lucky, and knows it.
"If I could help prevent somebody else from going through what I might have gone through, worse than what I went through, that's the main goal."
Health decisions that affect millions of men shouldn't depend on a doctor's unexplainable hunch or a spouse's persistence. When the system's own guidelines would have let a 33-year-old's cancer grow in silence, the system deserves harder questions, and men deserve clearer answers.
